BIIB:NASDAQBiogen Inc. Analysis
Data as of 2026-03-10 - not real-time
$189.07
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Biogen (BIIB) is trading at $189.07, comfortably above its 20‑day ($191.02) and 50‑day ($183.43) SMA, and sits near the upper end of its recent support zone at $181.24. The stock shows a bullish trend direction but a bearish MACD (histogram –1.04, signal line above the MACD line) and a neutral RSI of 51.8 suggest limited upside in the near term. Volatility remains high at 38% over the past 30 days while beta is modest at 0.67, indicating the share moves less than the market but can still swing sharply on news.
Fundamentally, Biogen’s forward PE of 11.6 and a DCF‑derived fair value of $167.32 imply the market is pricing in a premium (~13% above fair value) despite a 7.1% revenue decline and a solid profit margin of 13%. The company holds $3.8B in cash against $6.66B of debt (debt‑to‑equity 36.5), and analysts collectively rate it a Buy with a median price target of $206.5, indicating about 9% upside potential.
Fundamentally, Biogen’s forward PE of 11.6 and a DCF‑derived fair value of $167.32 imply the market is pricing in a premium (~13% above fair value) despite a 7.1% revenue decline and a solid profit margin of 13%. The company holds $3.8B in cash against $6.66B of debt (debt‑to‑equity 36.5), and analysts collectively rate it a Buy with a median price target of $206.5, indicating about 9% upside potential.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near strong support at $181.24
- Bearish MACD histogram indicating potential pullback
- Decreasing volume trend reducing short‑term liquidity
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward EPS growth driving a low forward PE of 11.6
- Analyst consensus Buy with median target $206.5 (~9% upside)
- Robust pipeline and recent product launches boosting revenue outlook
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Revenue contraction of 7.1% and high debt levels
- Long‑term pipeline and collaborations offering growth potential
- Regulatory and clinical trial risk inherent to biotech sector
Key Metrics & Analysis
Financial Health
Revenue Growth-7.10%
Profit Margin13.07%
P/E Ratio21.5
ROE7.39%
ROA6.14%
Debt/Equity36.47
P/B Ratio1.5
Op. Cash Flow$2.2B
Free Cash Flow$2.0B
Industry P/E25.3
Technical Analysis
TrendBullish
RSI51.8
Support$181.24
Resistance$200.29
MA 20$191.02
MA 50$183.43
MA 200$154.68
MACDBearish
VolumeDecreasing
Fear & Greed Index80.68
Valuation
Fair Value$167.32
Target Price$205.67
Upside/Downside8.78%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.67
Volatility38.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.